Both Cordis Corp., a subsidiary of Johnson & Johnson, New Brunswick, N.J., and Boston Scientific, Natick, Mass., claimed victories in the latest ruling in the companies' long-running stent patent dispute. A judge in U.S. District Court, Wilmington, Del., upheld two separate jury rulings that said each company infringed on the other's stent patents. The judge also denied a Boston Scientific motion for reconsideration of a dismissed patent lawsuit against Cordis. One jury found that Boston Scientific's drug-eluting Taxus stent and bare-metal stents infringe on a patent for Cordis' balloon expandable stent. Another jury found Cordis' stent products, including its Cypher drug-eluting stent, infringe on a Boston Scientific patent. In a news release, Cordis said it would appeal the ruling; by deadline Boston Scientific had not commented on whether it will appeal. Trial dates for damages weren't set. Cordis and Boston Scientific have the only drug-eluting stents on the market. -- by Joseph Mantone
Cordis, Boston Scientific both claim patent victories
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.